Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops.

Document Cited in Related
Vincent

MANews-(C)2009-2021

US-based ophthalmic focused healthcare company Harrow Health, Inc. (NASDAQ: HROW) has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines from Swiss drugmaker Novartis (NYSE: NVS), the company said.

The acquired medicines include Iopidine 1% and 0.5% (apraclonidine hydrochloride), and Maxitrol (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and Moxeza 0.5% (moxifloxacin hydrochloride).

The acquired products, which will be sold, marketed, and distributed through Harrow's wholly owned subsidiary, ImprimisRx, combined with the company's existing ophthalmic focused product portfolio, support Harrow's growing ophthalmic surgical and acute care market presence.

Under the terms of the agreement, after closing, Harrow and Novartis will immediately begin a transition period where Novartis will continue to sell the products and transfer the net profit to Harrow.

Following the transition period, Harrow expects to have the products manufactured by third parties and commercialize the products for the US market, while Novartis will retain all rights to the products outside of...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT